SAR progress is made in quinazolinone-based potential therapeutics for treating visceral leishmaniasis
July 26, 2023
Sandfly bites transmit the intracellular protozoan Leishmania to cause leishmaniasis that exhibits with clinical presentations ranging from a cutaneous ulcer to treatment-resistant lethal systemic disease (visceral leishmaniasis; VL). VL reportedly kills 20,000 to 30,000 every year according to the World Health Organization, where current medications are limited by side effects and evolving antibiotic resistance. Accordingly, there is a great need to develop alternatives.